Government officials in Germany have approved the prescription-to-non-prescription switch of GlaxoSmithKline’s naratriptan hydrochloride for the relief of migraine symptoms.

Naratriptan 2.5mg tablets will be available in Germany beginning April 1, in maximum package sizes of two tablets, or 5mg, according to a report from the Consumer and Healthcare Products Association.

It had been expected that the switch would have gone into effect January 1, but the parliamentary order includes an extra phase for manufacturers to alter labeling and product information, according to the CHPA.

The UK’s Medical and Healthcare products Regulatory Agency (MHRA) has also said it will look at triptan switching, and has asked for comments on proposed over-the-counter use of GSK’s sumatriptan and AstraZeneca’s zolmitriptan.